Pune: Emcure Pharmaceuticals (BSE: 544210, NSE: EMCURE) has reported a strong start to FY26, with consolidated revenue from operations reaching ₹2,101 crore in Q1 (Emcure Pharmaceuticals Q1 FY26), marking a 15.7% year-on-year growth.
The company’s Profit After Tax (PAT) stood at ₹215 crore, reflecting a 41% increase compared to the same quarter last year.
Also Read: UDENYCA Acquired by Intas Pharmaceuticals and Accord BioPharma in Biosimilar Expansion
Emcure Pharmaceuticals Q1 FY26 performance was bolstered by healthy momentum across both domestic and international markets. The company’s EBITDA rose by 20.1%, with margins improving to 19.2%.
The international business posted a stellar 22.1% growth, contributing ₹1,106 crore to total revenue. Notably, the Rest of the World segment surged by 42%, while the Canada business grew 16.4%, driven by successful new product launches and market share expansion.
Emcure’s European operations grew 12.8%, benefitting from early gains from new products.
On the domestic front, Emcure recorded ₹995 crore in revenue, a 9.4% YoY growth. Emcure Pharmaceuticals Q1 FY26 performance was supported by strength in key therapy areas and new initiatives in dermatology and over-the-counter (OTC) segments.
Also Read: Emcure Secures Exclusive Distribution Rights for Sanofi India’s Oral Anti-diabetic Drugs
During the quarter, the company deepened its strategic partnership with Sanofi, expanding distribution rights to include its Oral Anti-diabetic portfolio, alongside the existing cardiovascular products.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, commented: “We delivered robust performance across all businesses in Q1. Our expanded partnership with Sanofi positions us strongly in the fast-growing metabolic segment. With an exciting pipeline for both domestic and international markets, and a continuous focus on operational efficiency, we are well-placed to drive sustained margin improvement and long-term growth.”
With a strategic focus on in-licensing and in-house development, Emcure continues to build a strong product pipeline to support its expansion across key global markets.
Emcure Pharmaceuticals Q1 FY26: Revenue Break-Up
| Rs Cr | 1Q26 | 1Q25 | YOY% | 4Q25 | QOQ% |
| Revenue from operations | 2,101 | 1,815 | 15.7% | 2,116 | -0.7% |
| Domestic | 995 | 909 | 9.4% | 929 | 7.1% |
| International | 1,106 | 906 | 22.1% | 1,187 | -6.9% |
| EM | 360 | 254 | 41.9% | 481 | -25.1% |
| EU | 403 | 358 | 12.8% | 396 | 1.9% |
| CA | 342 | 294 | 16.4% | 310 | 10.1% |
Emcure Pharmaceuticals Q1 FY26: Performance Summary (Consolidated)Rs Cr 1Q26 1Q25 YOY% 4Q25 QOQ% Revenue from operations 2,101 1,815 15.72% 2,116 -0.74% Material Cost 802 683 17.41% 892 -10.10% Gross Profit 1,299 1,132 14.71% 1,224 6.08% Gross Profit Margins 61.8% 62.4% 57.8% Employee Costs 393 350 12.29% 373 5.39% Other expenses 501 445 12.54% 461 8.75% EBITDA 404 336 20.09% 390 3.58% EBITDA Margins 19.23% 18.53% 18.43% Other Income 4 23 4 Depreciation and Amortisation 99 94 97 Finance Costs inc. Forex 14 59 26 Exceptional Items 4 0 10 Profit Before Tax (PBT) 291 207 40.19% 261 11.57% Tax 76 55 63 Profit After Tax (PAT) 215 153 40.76% 197 8.90% PAT Margins 10.2% 8.4% 9.3%
